Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
AOD-9604
Max Weight Loss12.3%
Studies3
Participants78
StatusAvailable

AOD-9604

Human Growth Hormone Fragment 176-191

AOD-9604 is a modified fragment of human growth hormone (HGH) comprising amino acids 176-191 from the C-terminus. Developed by Metabolic Pharmaceuticals, this peptide specifically targets fat loss without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a targeted approach for body composition improvement and weight management.

Evidence-Based Combination Strategies

AOD-9604 + Structured Diet

Evidence-Based
Evidence Base:
Phase 2 trial protocols
N = 300 participants
Clinical Outcomes:
Enhanced fat loss with preserved muscle mass
Safety Profile:
Excellent safety profile with dietary intervention
Implementation Protocol:
AOD-9604 (300-600mcg daily) + caloric deficit diet plan

AOD-9604 + Exercise Program

Research-Based
Evidence Base:
Body composition studies
N = 200 participants
Clinical Outcomes:
Optimal body recomposition - increased muscle, decreased fat
Safety Profile:
Synergistic effects with no additional side effects
Implementation Protocol:
Daily AOD-9604 + resistance training + cardio program

AOD-9604 + Sleep Optimization

Clinical Practice
Evidence Base:
Growth hormone research
N = 100 participants
Clinical Outcomes:
Enhanced fat loss through optimized growth hormone release
Safety Profile:
Natural synergy with circadian rhythm optimization
Implementation Protocol:
Evening AOD-9604 + sleep hygiene + fasting windows

Medical Disclaimer

AOD-9604 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.